

Figure S1. Characterization of Antibody Immune Response Against HBV, Related to Figure 1

(A) Schematic representation of different stages of HBV infection. Vaccinated or infected naturally recovered individuals were recruited for this study.

(B) Sera (1:50 dilution in the final assay volume) from 159 volunteers were screened, see also Figure 1A.

(C-E) Comparison of anti-HBs ELISA titers (upper panel) and their serum neutralization capacity (lower panel) between different groups of individuals. Vaccinated or recovered individuals show statistically higher anti-HBs titers (upper panel, C) and more potent neutralizing activity (lower panel, C) than the uninfected unvaccinated individuals. Younger individuals (≤ 45 years old) showed slightly higher antibody immune response against HBsAg (D). No difference was found between genders (E).




Figure S2. Antibody Cloning and Sequence Analysis of Anti-HBs, Related to Figure 2

(A) Frequency of S-protein-specific memory B cells in peripheral blood mononuclear cells of all twelve donors. Details are similar to Figure 2A.

(B) Pie charts show the distribution of anti-HBs antibodies. Figure legends are similar to Figure 2C. VH and VL genes for each slice are shown and the 20 chosen anti-HBs antibodies are labeled.

(C) Phylogenetic tree of all cloned anti-HBs antibodies based on IGH Fab region. IGH Fab regions from 244 memory B cells sorted with HBsAg were aligned followed by tree construction.




Figure S3. Autoreactivity of 20 anti-HBs antibodies, Related to Figure 3

(A) Autoreactivity of monoclonal antibodies. Positive control antibody efficiently stained the nucleus of HEp-2 cells. Twenty anti-HBs antibodies, as well as anti-HBs antibody libivirumab and anti-HIV antibody 10-1074, were also tested.

(B) Polyreactivity profiles of 20 anti-HBs antibodies. ELISA measures antibody binding to the following antigens: double-stranded DNA (dsDNA), insulin, keyhole limpet hemocyanin (KLH), lipopolysaccharides (LPS), and single-stranded DNA (ssDNA). Red and green lines represent positive control antibody ED38 and negative

control antibody mG053 respectively, while dashed lines show cut-off values for positive reactivity (Gitlin et al., 2016).

Figure S4. Alanine Scanning and Peptide Screening, Related to Figure 4

(A) Results of ELISA on alanine scanning mutants of HBsAg. Binding to mutants was normalized to wild-type S-protein: black, 0-25%; dark grey, 26-50%; light grey, 51-75%; white, >76%. Experiments were performed three times. Underlined cysteines, alanines, and amino acids known to be critical for S-protein production were not mutated (Salisse and Sureau, 2009).

(B) Schematic diagram of alanine scanning results.




Figure S5. *In Vitro* Neutralization Assay of anti-HBs bNAbs Unmutated Common Ancestor Antibodies or Combinations, Related to Figure 5

(A-B) *In vitro* neutralization assay of anti-HBs bNAbs and their corresponding unmutated common ancestor (UCA) antibodies. The relative infection rates were calculated based on either HBsAg protein level in culture medium (A) or HBcAg staining intracellularly (B).

(C) *In vitro* neutralization assay of anti-HBs bNAbs recognizing different epitopes and the same total amount of antibody combination at 1:1 or 1:1:1 ratio.




Figure S6. Detailed Information of Crystal Structure of H015 and Its Linear Epitope, Related to Figure 6

(A) Synthesized peptides for antigenic loop region were subjected to ELISA for antibody binding. Among the tested antibodies, only H015 binds peptide-11 and -12.

(B) Data collection and refinement statistics for H015 Fab are summarized. Statistics for the highest-resolution shell are shown in parentheses. Refinement program PHENIX 1.16.

(C) The green/red density is the unbiased omit map. Red is negative density equated to noise.

(D) Table of contacts within the peptide and between Fab fragment and peptide.







Figure S7. HBV DNA levels and S-protein Sequences in Antibody-Treated huFNRG Mice, Related to Figure 7

(A) HBV DNA levels in representative individual huFNRG mice treated by control antibody 10-1074, anti-HBs bNAb H020, anti-HBs bNAb H007, combination of anti-HBs bNAb (H006 + H007), (H017 + H019), and (H016 + H017 + H019). HBV DNA levels in mouse sera were monitored on a weekly basis. The mice without red arrows bear no escape mutations at the last time point.

(B) Part of the S-protein sequences from the indicated mice (red arrows and numbers) are shown below as chromatograms, with mutations marked by red arrowheads.

(C-D) HBsAg levels in mouse sera before and after antibody infusion. Mice were treated by anti-HBs combination H017 + H019 (C) (see Figure 7K) and H016 + H017 + H019 (D) (see Figure 7L). Each line represents a mouse with concentrations of serum HBsAg level expressed in NCU/ml (national clinical units per milliliter).